What technical signals does Biotoxtech (086040) have?

Biotoxtech current technical signals: no active technical signal.

Is Biotoxtech a cup-and-handle pattern?

No. Biotoxtech has no valid cup-and-handle signal right now.

What are Biotoxtech's financials and valuation?

Biotoxtech's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Biotoxtech

086040 · KOSDAQ

₩2,390-1.04%

2026-09-04 close

Biotoxtech last closed at ₩2,390 (-1.04%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…

No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions

303 picks

Next-day win rate

50.7%

Avg next-day

-0.11%

vs market

-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

EntryAccount sizeStopTarget (optional)Risk per trade (%)

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

Overall: 건강관리 229/291 · top 79%

Factor composite · relative position in sector

PER — · PBR 0.95 — own-history percentile 0/100 · 93/100

Open self-history band

PER0/100

PBR93/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024

Distress zoneFinancial-metric reference signal

Altman Z'' zoneZ'' -1.10

Distress

Grey

Safe

The marker shows the current Z'' value within the displayed zones.

Altman Z'': -1.10
Beneish M-Score: -2.35
Sloan accrual: 0.51%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

2/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score2/9

Profitability

Positive ROANot passed
Positive OCFNot passed
Improving ΔROANot passed
Accruals (OCF > net income)Not passed

Leverage & liquidity

Lower debtNot passed
Higher current ratioNot passed
No new sharesNot passed

Efficiency

Higher gross marginPass
Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -17%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 173 of 287, share 0.1%.

173 / 2870.1%revenue share

Who dominates this industry?

1삼성바이오로직스7.3%
2셀트리온5.7%
3녹십자홀딩스3.5%
4유한양행3.3%
5대웅3.1%
6바이오톡스텍0.1%

Concentration

DistributedCR3 16.6%

HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p: 31.61
Direction: 확대
Level: 넓음
Years: 7

Value lens

P90/P10: 13.9
Median P/B: 1.47
Level: 넓음
n: 263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin: -20.6%
Interest coverage: -1.7x
Return on equity (ROE): -16%

Operating margin −5pp

Operating loss

Interest coverageBase -1.7x-2.1x

Return on equity (ROE)Base -16%-39.1%

Revenue −15%

Interest coverage risk

Interest coverageBase -1.7x-1.4x

Return on equity (ROE)Base -16%-30.8%

Interest rate +2pp

Interest coverage risk

Interest coverageBase -1.7x-1.2x

Return on equity (ROE)Base -16%-38.7%

Interest coverage limit

Already below the limit by 32.9pp

Interest coverage limit at an operating margin of 12.3%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-19

Suppliers disclosed by the company in its 2026-03-19 annual report.

Suppliers without disclosed amount

바이오톡스텍CROBeagleGuineaPigRabbitMouseRat

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

강종구24.03%2026-08-06 · 증감 +0.06%p

Connections

AI-extracted related companies · for reference

Customers

삼성바이오로직스Price comovement r=0.21 (1 year)셀트리온Price comovement r=0.42 (1 year)SK바이오사이언스Price comovement r=0.35 (1 year)유한양행Price comovement r=0.36 (1 year)한미약품Price comovement r=0.23 (1 year)대웅제약Price comovement r=0.28 (1 year)GC녹십자동아에스티Price comovement r=0.35 (1 year)아이큐어

Same theme

한국바이오켐씨젠Price comovement r=0.31 (1 year)랩지노믹스코스맥스바이오바이오니아Price comovement r=0.31 (1 year)

🔗 See in the full market map →

Recent filings

Biotoxtech's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About Biotoxtech

What technical signals does Biotoxtech (086040) have?: Biotoxtech current technical signals: no active technical signal.
Is Biotoxtech a cup-and-handle pattern?: No. Biotoxtech has no valid cup-and-handle signal right now.
What are Biotoxtech's financials and valuation?: Biotoxtech's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy